Amryt

Showing 2 posts of 2 posts found.

shutter

Amryt’s Lojuxta approved in Brazil to reduce cholesterol in homozygous familial hypercholesterolaemia patients

December 9, 2020
Research and Development, Sales and Marketing Amryt, Brazil, rare disease

Brazil’s National Health Surveillance Agency (ANVISA) has moved to authorise Amryt’s Lojuxta (lomitapide) in the country as a treatment for …

shutterstock_36423250

Promising interim Phase 3 data spurs epidermolysis bullosa trial expansion for Amryt

January 7, 2019
Research and Development, Sales and Marketing Amryt, epidermolysis bullosa, pharma, rare disease

Rare disease firm Amryt has announced interim efficacy data for its epidermolysis bullosa (EB) therapy AP101, showing that things are …

The Gateway to Local Adoption Series

Latest content